LRRK2
Les inhibiteurs de LRRK2 sont des composés qui ciblent et inhibent l'activité de la Leucine-Rich Repeat Kinase 2 (LRRK2), une enzyme impliquée dans plusieurs processus cellulaires, y compris l'autophagie, le trafic vésiculaire et l'inflammation. Les mutations du gène LRRK2 sont associées à un risque accru de développer la maladie de Parkinson, ce qui fait de LRRK2 une cible importante pour la recherche sur les maladies neurodégénératives. Les inhibiteurs de LRRK2 sont essentiels pour explorer son rôle dans la maladie de Parkinson et pour développer des stratégies thérapeutiques potentielles. Chez CymitQuimica, nous offrons une sélection d'inhibiteurs de LRRK2 pour soutenir vos recherches en neurodégénérescence, signalisation des kinases et développement thérapeutique.
48 produits trouvés pour "LRRK2".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
BIX 02565
CAS :BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).Formule :C26H30N6O2Degré de pureté :97.44% - 99.7%Couleur et forme :SolidMasse moléculaire :458.5554MLi-2
CAS :MLi-2: Novel, potent CNS-active LRRK2 inhibitor; IC50s: 0.76nM in vitro, 1.4nM cellular, 3.4nM binding.Formule :C21H25N5O2Degré de pureté :98.96% - 99.07%Couleur et forme :SolidMasse moléculaire :379.4555RN277
RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research.Couleur et forme :Odour SolidPROTAC LRRK2 Degrader-3
CAS :PROTACLRRK2 Degrader-3 is a PROTACLRRK2 degrader with a DC50 of 0.17 nM. This compound can be utilized in research related to Parkinson's disease and inflammation.Formule :C44H54N10O5Masse moléculaire :802.98PROTAC LRRK2 Degrader-5
CAS :PROTAC LRRK2 Degrader-5 Formula (V) is an LRRK2 PROTAC degrader. It can be utilized in the research of diseases associated with LRRK2, such as Parkinson's disease (PD).Formule :C46H57FN10O4Masse moléculaire :833.01XL01126
CAS :XL01126 LRRK2 degrader (DC50 14 nM G2019S, 32 nM WT) BBB-penetrant probe for Parkinson’s disease and LRRK2 signaling and protein degradation studies.Formule :C50H64ClFN10O6S2Degré de pureté :99.98%Couleur et forme :SolidMasse moléculaire :1019.69CZC-54252 hydrochloride
CAS :CZC-54252 hydrochloride: selective LRRK2 inhibitor; IC50 = 1.85/1.28 nM (wild-type/G2019S); neuroprotective; EC50 = 1 nM for G2019S injury.Formule :C22H26Cl2N6O4SDegré de pureté :99.28%Couleur et forme :SolidMasse moléculaire :541.45RN341
RN341 is a LRRK2-specific type II kinase inhibitor (IC50 of 296 nM). It prevents the phosphorylation of LRRK2 by stabilizing an open conformation, thereby avoiding S935 dephosphorylation. Additionally, RN341 rescues LRRK2-mediated kinesin motility blockage by preventing microtubule binding. This compound effectively inhibits both wild-type and G2019S LRRK2 at the cellular level, offering a novel avenue for Parkinson's disease research.Couleur et forme :Odour SolidEB-42486
CAS :EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.Formule :C22H22N8ODegré de pureté :99.53%Couleur et forme :White SolidMasse moléculaire :414.4631PROTAC LRRK2 Degrader-4
CAS :PROTACLRRK2 Degrader-4 is a PROTACLRRK2 degrader with a DC50 of 0.79 nM, employed in research related to Parkinson's disease and inflammation.Formule :C45H56N10O5Masse moléculaire :817.01FX 2149
CAS :FX 2149 is a GTP-binding inhibitor that potently inhibits LRRK2 GTP binding and kinase activity in vitro and attenuates the toxic effects of LRRK2 in Parkinson’s disease models.Formule :C15H17N3O3SDegré de pureté :99.94%Masse moléculaire :319.38Nictide
CAS :Nictide, a peptide substrate for LRRK2 (leucine-rich repeat protein kinase-2), undergoes phosphorylation by the activated form of LRRK2[G2019S], exhibiting a Km value of 10 μM.Formule :C123H193N45O28Couleur et forme :SolidMasse moléculaire :2750.13JH-XII-03-02
CAS :JH-XII-03-02 is a potent and selective leucine-rich repeat kinase 2 (LRRK2) proteolysis targeting chimera (PROTAC) degrader, utilized in Parkinson's Disease (PDFormule :C43H51N9O10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :853.92PROTAC LRRK2 Degrader-2
CAS :PROTAC LRRK2 Degrader-2 is a PROTAC-based degrader targeting LRRK2 with a DC50 of 0.14 nM. It recruits LRRK2 or its mutants to cereblon E3 ubiquitin ligase, facilitating the targeted ubiquitination and subsequent proteasomal degradation of LRRK2. PROTAC LRRK2 Degrader-2 is applicable in Parkinson's disease research.Formule :C43H53N11O5Masse moléculaire :803.95PROTAC LRRK2 Degrader-1
CAS :PROTAC LRRK2 Degrader-1 (compound 18) is a PROTAC degrader targeting leucine-rich repeat kinase 2 (LRRK2) with an IC50 of less than 10 nM. It is applicable for research in Parkinson's disease.Formule :C45H54FN9O5Masse moléculaire :819.97CC-3240
CAS :CC-3240 (compound 13), a molecular glue degrader of CaMKK2 based on CC-8977, has an IC50 of 9 nM [1].Formule :C52H64N6O7SCouleur et forme :SolidMasse moléculaire :917.17Anti-LRRK2 Antibody (1C773)
Anti-LRRK2 Antibody (1C773) is an antibody targeting LRRK2. Anti-LRRK2 Antibody (1C773) can be used in ELISA, IHC.Couleur et forme :Odour LiquidGNE-7915 tosylate
CAS :GNE-7915 tosylate is a potent, selective, and brain-penetrant LRRK2 inhibitor, boasting an IC50 value of 9 nM.Formule :C26H29F4N5O6SCouleur et forme :SolidMasse moléculaire :615.597HG-10-102-01
CAS :HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).Formule :C17H20ClN5O3Degré de pureté :99.59%Couleur et forme :SolidMasse moléculaire :377.825LRRK2-IN-1
CAS :LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.Formule :C31H38N8O3Degré de pureté :98% - 98.82%Couleur et forme :SolidMasse moléculaire :570.69
